Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GMNN | O75496 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | CETP | P11597 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.46 |
| ▸ | CCR6 | P51684 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | UBE2N | P61088 | 2/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7066234 | 0.96 | DGKA (0.65) | DGKAUSP2FAAHMEN1KMT2A | |
| SCHEMBL7065278 | 0.96 | DGKA (0.65) | DGKAUSP2FAAHMEN1KMT2A | |
| Oleyl Alcohol SCHEMBL28097800 | 0.92 | DGKA (0.60) | DGKAUSP2FAAHMEN1KMT2A | |
| SCHEMBL14313909 | 0.90 | DGKA (0.58) | DGKAUSP2FAAHMEN1KMT2A | |
| Olealdehyde SCHEMBL632824 | 0.90 | DGKA (0.62) | DGKAUSP2FAAHMEN1KMT2A | |
| SCHEMBL28342030 | 0.89 | DGKA (0.55) | DGKAUSP2FAAHMEN1KMT2A | |
| SCHEMBL17237750 | 0.89 | USP2 (0.75) | DGKAUSP2FAAHALDH1A1CNR1 | |
| SCHEMBL17237747 | 0.89 | USP2 (0.75) | DGKAUSP2FAAHALDH1A1CNR1 | |
| SCHEMBL1962549 | 0.88 | USP2 (0.80) | DGKAUSP2FAAHALDH1A1CNR1 | |
| SCHEMBL1704928 | 0.88 | DGKA (0.60) | DGKAUSP2FAAHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102040621-B | Lipid oxide and the application in treatment inflammatory diseases thereof | CANALIS-HAEMALIS BIOGROWTH LTD. (IL) | 2016-01-20 | — | — | CN | disclosed |
| US-8563534-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2013-10-22 | — | — | US | disclosed |
| US-8501715-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2013-08-06 | — | — | US | disclosed |
| EP-1626728-B1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD (IL) | 2013-07-10 | — | — | EP | disclosed |
| US-20120329757-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2012-12-27 | — | — | US | disclosed |
| US-8158611-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2012-04-17 | — | — | US | disclosed |
| EP-2425841-A1 | Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis | Vascular Biogenics Ltd. (IL) | 2012-03-07 | — | — | EP | disclosed |
| US-20110189212-A1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2011-08-04 | — | — | US | disclosed |
| US-7973023-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2011-07-05 | — | — | US | disclosed |
| CN-102040621-A | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD | 2011-05-04 | — | — | CN | disclosed |
| US-20090209775-A1 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD. (IL) | 2009-08-20 | — | — | US | disclosed |
| US-7504388-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2009-03-17 | — | — | US | disclosed |
| US-20080261865-A1 | Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders | VASCULAR BIOGENICS LTD. (IL) | 2008-10-23 | — | — | US | disclosed |
| US-20070099868-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2007-05-03 | — | — | US | disclosed |
| US-7186704-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2007-03-06 | — | — | US | disclosed |
| US-20050272813-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2005-12-08 | — | — | US | disclosed |
| US-6838452-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2005-01-04 | — | — | US | disclosed |
| CN-1529605-A | Methods of use for the prevention and treatment of atherosclerosis and compositions containing defined oxidized phospholipids | — | 2004-09-15 | — | — | CN | disclosed |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2004-06-03 | — | — | US | disclosed |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189212-A1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | ALOX15B, GPX4, ALOX12 | DGKA 559/4885USP2 1937/4885FAAH 835/4885 |
| US-20050272813-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | DGKA 355/4885USP2 1194/4885FAAH 517/4885 |
| US-20120329757-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | DGKA 355/4885USP2 1194/4885FAAH 517/4885 |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | DGKA 355/4885USP2 1194/4885FAAH 517/4885 |
| US-20080261865-A1 | Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders | ALOX15B, GPX4, ALOX12 | DGKA 559/4885USP2 1937/4885FAAH 835/4885 |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | DGKA 355/4885USP2 1194/4885FAAH 517/4885 |
| US-20070099868-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | ALOX15B, GPX4, ALOX12 | DGKA 559/4885USP2 1937/4885FAAH 835/4885 |
| US-20090209775-A1 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | PHOSPHO1, GPX4, SGMS1 | DGKA 355/4885USP2 1194/4885FAAH 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.